Condition (MeSH)
Acute Chest Syndrome
ClinicalTrials.gov lists 40 trials for Acute Chest Syndrome or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
40 of the 40 trials are tagged with Acute Chest Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Acute Chest Syndrome trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 4 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 1 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 25 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Acute Chest Syndrome trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Not applicable | 10 |
| Observational | 10 |
How many Acute Chest Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 7 |
| Completed | 19 |
| Terminated | 6 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Acute Chest Syndrome trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Alexhander Izhaki | 1 |
| Anthera Pharmaceuticals | 1 |
| AstraZeneca | 1 |
| CSL Behring | 1 |
Which drugs are being tested for Acute Chest Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nitric Oxide | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| tocilizumab SC | 2 |
| EC Aspirin | 1 |
| Daily oral vitamin D3, 3,333 IU | 1 |
| Active Comparator: Vitamin D3 12,000 IU | 1 |
| Ticagrelor (Brilique) 90 | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Acute Chest Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Brain Injury | 52 | 1 |
| Pneumonia | 46 | 3 |
| Pneumothorax | 38 | 1 |
| Other Respiratory | 24 | 1 |
| Pulmonary Embolism | 23 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Acute Chest Syndrome? (41)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Validation and Application of a Predictive Score of Acute Chest Syndrome. | NEJM evidence | 2026 | Yes |
| Characteristics and outcomes of children and young adults with sickle cell disease supported with extracorporeal membrane oxygenation (ECMO): An updated analysis of the ELSO registry. | Artificial organs | 2025 | Yes |
| Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Double-Blind Controlled Randomized Clinical Trial. | American journal of respiratory and critical care medicine | 2025 | Yes |
| High flow oxygen for vaso-occlusive crisis: a multicentre, prospective, randomised, multi-arm, multi-stage clinical trial (OSONE). | BMJ open | 2025 | Yes |
| Lung Ultrasound in Sickle Cell: Sounds Like an Improvement in Acute Chest Diagnosis. | Chest | 2023 | Yes |
Showing 5 of 41 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.